[ad_1]
Intec Pharma (NASDAQ: NTEC) and Aytu Bioscience (NASDAQ: AYTU) are two small cap medical companies, but what is the best investment? We will compare the two companies according to the strength of their badyst recommendations, valuation, profitability, risk, dividends, profits and institutional ownership.
Risk and Volatility
Intec Pharma has a beta of 1, which suggests that its stock price has a volatility profile similar to that of the S & P 500. Comparatively, Aytu Bioscience has a beta of 6.67, suggesting that the price of its shares is 567% more volatile than the S & P 500.
Assessment and income
This table compares revenues, earnings per share (EPS) and valuation of Intec Pharma and Aytu Bioscience.
| Gross revenue | Price / Sales Report | Net revenue | Earnings per share | Ratio Price / Profit | |
| Intec Pharma | N / A | N / A | – $ 29.09 million | ($ 1.65) | -3.64 |
| Aytu Bioscience | $ 3.66 million | 0.60 | – $ 10.18 million | ($ 27.94) | -0.04 |
Aytu Bioscience has higher revenues and revenues than Intec Pharma. Intec Pharma is trading at a price / earnings ratio lower than that of Aytu Bioscience, indicating that it is currently the most affordable of the two stocks.
Institutional property and initiated
45.1% of Intec Pharma's shares are owned by institutional investors. 5.8% of Aytu Bioscience's shares are held by insiders. Strong institutional ownership is an indication that large financial managers, hedge funds and endowment funds believe that one stock will outperform the market in the long run.
Profitability
This table compares the net margins, return on equity, and return on badets of Intec Pharma and Aytu Bioscience.
| Net Margins | Return on equity | Return on badets | |
| Intec Pharma | N / A | -63.39% | -57.89% |
| Aytu Bioscience | -277.44% | -148.91% | -62.63% |
Analyst Rating
This is a summary of current ratings and pricing targets for Intec Pharma and Aytu Bioscience, provided by MarketBeat.
| Sales notes | Hold evaluations | Buy Reviews | Strong buy odds | Evaluation score | |
| Intec Pharma | 0 | 0 | 5 | 0 | 3.00 |
| Aytu Bioscience | 0 | 0 | 1 | 0 | 3.00 |
Currently, Intec Pharma has a price target set at USD 12.88, which indicates a upside potential of 114.58%. Aytu Bioscience has a consensus price target of USD 10.00, which indicates a potential upside of 719.67%. Given the potential improvement in Aytu Bioscience's potential, badysts clearly believe that Aytu Bioscience is more supportive than Intec Pharma.
summary
Intec Pharma defeat Aytu Bioscience on 6 out of 11 factors compared between the two actions.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical-stage biopharmaceutical company, focuses on drug development based on its patented Accordion Pill platform technology in Israel. The Accordion pill is an oral drug delivery system designed to improve the effectiveness and safety of existing drugs and drugs being developed using a specific gastric retention and release mechanism. The company's lead product candidate is the Accordion Pill Carbidopa / Levodopa (AP-CDLD), which is currently undergoing a Phase III clinical trial for the treatment of symptoms of Parkinson's disease. Parkinson's disease in patients with advanced Parkinson's disease. He is also developing the Zaleplon Accordion Pill (AP-ZP), which is currently undergoing a Phase III clinical trial for the treatment of insomnia, including induction of sleep, and for the improvement of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of ulcers induced by the nonsteroidal anti-inflammatory drug and small intestine; and the Accordion Pill platform with cannabidiol and 9-tetrahydrocannabinol (AP-CBD / THC), which is currently undergoing a phase I clinical trial for the treatment of various indications, including the neuropathic pain in the lower back and fibromyalgia. The company, formerly known as Intec Pharmaceuticals (2000) Ltd., was renamed Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Aytu Bioscience Company Profile
Aytu BioScience, Inc., specialized health company, focuses on the development and commercialization of new products in the field of hypogonadism (low testosterone), insomnia and l? male infertility in the United States and around the world. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic sperm test used in measuring the potential for static oxidation reduction in human sperm. In addition, the company provides the MiOXSYS badyzer, a lightweight, portable office platform used in clinical research or research laboratories or near a patient care area; and MiOXSYS disposable sensors. The company is based in Englewood, Colorado.
Get news and reviews for Intec Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and badyst reviews for Intec Pharma and related companies with MarketBeat.com's FREE daily e-newsletter.
Source link
